Unicancer R&D publications


FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

T. Conroy et al, N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.


Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant ...

J. Bennouna et al, Clin Colorectal Cancer. 2018 Oct 19. doi: 10.1016/j.clcc.2018.09.011.


Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A ...

JC Faivre et al, Radiother Oncol. 2018 Aug 29. doi: 10.1016/j.radonc.2018.08.008


An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

Péron J et al., Oncotarget. 2016 Dec 13;7(50):82953-82960.


Applying the Longitudinal Model from Item Response Theory to Assess the Health-Related Quality of Life in the ...

Barbieri A et al., Med Decis Making. 2015 Dec 18. pii: 0272989X15621883


Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. ...

Gérard JP, et al., Radiother Oncol. 2015 May;115(2):246-52. doi: 10.1016/j.radonc.2015.04.003. Epub 2015 Apr 24.


Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced ...

Levy A, et al., Radiother Oncol. 2015 Mar;114(3):415-6. doi: 10.1016/j.radonc.2015.02.008. Epub 2015 Mar 11